PL2089364T3 - Związki pirydynonu - Google Patents
Związki pirydynonuInfo
- Publication number
- PL2089364T3 PL2089364T3 PL07844974T PL07844974T PL2089364T3 PL 2089364 T3 PL2089364 T3 PL 2089364T3 PL 07844974 T PL07844974 T PL 07844974T PL 07844974 T PL07844974 T PL 07844974T PL 2089364 T3 PL2089364 T3 PL 2089364T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridinone compounds
- pyridinone
- compounds
- Prior art date
Links
- 150000005299 pyridinones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85754006P | 2006-11-08 | 2006-11-08 | |
| PCT/US2007/084047 WO2008058229A1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
| EP07844974.1A EP2089364B1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2089364T3 true PL2089364T3 (pl) | 2013-11-29 |
Family
ID=39048786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07844974T PL2089364T3 (pl) | 2006-11-08 | 2007-11-08 | Związki pirydynonu |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7851489B2 (pl) |
| EP (1) | EP2089364B1 (pl) |
| JP (1) | JP5276005B2 (pl) |
| KR (1) | KR101390076B1 (pl) |
| CN (1) | CN101535264B (pl) |
| AR (1) | AR063628A1 (pl) |
| AU (1) | AU2007317296B2 (pl) |
| CA (1) | CA2669266C (pl) |
| CL (1) | CL2007003226A1 (pl) |
| DK (1) | DK2089364T3 (pl) |
| ES (1) | ES2424851T3 (pl) |
| HR (1) | HRP20130626T1 (pl) |
| MX (1) | MX2009004699A (pl) |
| NO (1) | NO342395B1 (pl) |
| PE (1) | PE20081490A1 (pl) |
| PL (1) | PL2089364T3 (pl) |
| PT (1) | PT2089364E (pl) |
| SI (1) | SI2089364T1 (pl) |
| TW (1) | TWI409259B (pl) |
| WO (1) | WO2008058229A1 (pl) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531396T3 (es) | 2008-01-23 | 2015-03-13 | Bristol Myers Squibb Co | Proceso para preparar compuestos de piridinona |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| HRP20150105T1 (hr) | 2010-04-30 | 2015-03-13 | Bristol-Myers Squibb Company | Farmaceutske kompozicije koje sadrže n-(4-(2-amino-3-hloropiridin-4-iloksi)-3-fluorofenil-l-(4-fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid |
| CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
| CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| HK1202450A1 (zh) | 2011-11-22 | 2015-10-02 | Deciphera Pharmaceuticals, Llc. | 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物 |
| EP2879677B1 (en) | 2012-07-28 | 2017-06-14 | Calitor Sciences, LLC | Substituted pyrazolone compounds and methods of use |
| US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) * | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3044366A1 (en) * | 2016-12-19 | 2018-06-28 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
| CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
| WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
| WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
| WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
| WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
| CN111372925B (zh) * | 2017-11-24 | 2022-09-02 | 南京明德新药研发有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| EP3762392B1 (en) | 2018-03-08 | 2024-05-15 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| KR20210090625A (ko) | 2018-10-09 | 2021-07-20 | 아슬란 파마슈티컬스 피티이 엘티디 | 바를리티닙의 말론산 염 |
| JP2022505272A (ja) * | 2018-10-19 | 2022-01-14 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | がん治療のためのトポイソメラーゼｉｉ触媒阻害剤化合物による治療、方法、及び使用 |
| EP3911320A4 (en) | 2019-01-15 | 2022-11-30 | The Translational Genomics Research Institute | PHOSPHONATE CONJUGATES AND USES THEREOF |
| EP4011885A4 (en) * | 2019-08-02 | 2023-01-18 | Wellmarker Bio Co., Ltd. | CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP2022554042A (ja) | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| JP2023513675A (ja) | 2020-02-06 | 2023-04-03 | ウェルマーカー・バイオ・カンパニー・リミテッド | Ｋｒａｓ変異に関連する癌の予防または治療のための医薬組成物 |
| US20230099204A1 (en) | 2020-03-03 | 2023-03-30 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
| US20230202992A1 (en) | 2020-05-18 | 2023-06-29 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same |
| WO2021235812A1 (ko) | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 비소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
| US20230242521A1 (en) | 2020-05-18 | 2023-08-03 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| WO2022169248A1 (ko) * | 2021-02-02 | 2022-08-11 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| US20240293386A1 (en) * | 2021-06-22 | 2024-09-05 | Lg Chem, Ltd. | Novel compound as protein kinase inhibitor |
| US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
| US20260217673A1 (en) * | 2022-12-23 | 2026-07-30 | Lg Chem, Ltd. | Novel compound as ron inhibitor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
| DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| CA2374995C (en) * | 1999-07-20 | 2010-12-07 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| US6355660B1 (en) * | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| EE200200119A (et) | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliini derivaadid ja nende kasutamine ravimitena |
| FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| SE0102384D0 (sv) * | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
| WO2003045921A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP2005263787A (ja) * | 2004-02-17 | 2005-09-29 | Ishihara Sangyo Kaisha Ltd | アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| EP1751136B1 (en) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007035428A1 (en) * | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active Active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es unknown
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 HR HRP20130626TT patent/HRP20130626T1/hr unknown
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en not_active Ceased
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090096423A (ko) | 2009-09-10 |
| HRP20130626T1 (en) | 2013-08-31 |
| AR063628A1 (es) | 2009-02-04 |
| JP5276005B2 (ja) | 2013-08-28 |
| MX2009004699A (es) | 2009-05-15 |
| US20080114033A1 (en) | 2008-05-15 |
| CA2669266C (en) | 2014-04-29 |
| ES2424851T3 (es) | 2013-10-09 |
| CN101535264B (zh) | 2012-11-28 |
| NO342395B1 (no) | 2018-05-14 |
| PT2089364E (pt) | 2013-08-26 |
| JP2010509362A (ja) | 2010-03-25 |
| EP2089364B1 (en) | 2013-06-12 |
| NO20091605L (no) | 2009-05-27 |
| TW200829564A (en) | 2008-07-16 |
| US20110052583A1 (en) | 2011-03-03 |
| CA2669266A1 (en) | 2008-05-15 |
| WO2008058229A1 (en) | 2008-05-15 |
| SI2089364T1 (sl) | 2013-10-30 |
| HK1131608A1 (en) | 2010-01-29 |
| PE20081490A1 (es) | 2008-10-30 |
| US7851489B2 (en) | 2010-12-14 |
| EP2089364A1 (en) | 2009-08-19 |
| DK2089364T3 (da) | 2013-09-02 |
| CN101535264A (zh) | 2009-09-16 |
| AU2007317296B2 (en) | 2012-07-05 |
| TWI409259B (zh) | 2013-09-21 |
| KR101390076B1 (ko) | 2014-04-29 |
| US8536200B2 (en) | 2013-09-17 |
| AU2007317296A1 (en) | 2008-05-15 |
| CL2007003226A1 (es) | 2008-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130626T1 (en) | Pyridinone compounds | |
| GB0608386D0 (en) | Compounds | |
| GB0608263D0 (en) | Compounds | |
| GB0602424D0 (en) | Compounds | |
| GB0602046D0 (en) | Compounds | |
| EP1984379A4 (en) | ANTI-ARENAVIRAL COMPOUNDS | |
| GB0605786D0 (en) | Compounds | |
| GB0606876D0 (en) | Compounds | |
| EP2082022A4 (en) | LINKS | |
| GB0605785D0 (en) | Compounds | |
| GB0605784D0 (en) | Compounds | |
| GB0606913D0 (en) | Compounds | |
| GB0602042D0 (en) | Compounds | |
| GB0602560D0 (en) | Compounds | |
| EP1973905A4 (en) | COMPOUNDS | |
| GB0600427D0 (en) | Compounds | |
| GB0602412D0 (en) | Compounds | |
| GB0605946D0 (en) | Compounds | |
| GB0604377D0 (en) | Compounds | |
| GB0600929D0 (en) | Compounds | |
| GB0608640D0 (en) | Compounds | |
| GB0605414D0 (en) | Compounds | |
| GB0605540D0 (en) | Compounds | |
| GB0605588D0 (en) | Compounds | |
| GB0602134D0 (en) | Compounds |